论文部分内容阅读
卵巢癌是女性生殖器官中常见的恶性肿瘤之一,是女性生殖系统肿瘤中的最大杀手。随着分子遗传学和肿瘤生物学研究的深入发展,基因诊断已成为治疗恶性肿瘤的重要手段。因此,研究卵巢癌的分子遗传学机制进而了解其生物学效应对卵巢癌的发生发展、治疗及预后等方面有重要意义。大量临床病理学和分子遗传学实验证明ERK1/2通路异常活动与低级浆液性卵巢癌的发生发展关系密切。文章将针对ERK1/2通路的异常持续活化(KRAS或BRAF突变次级效应)与低级浆液性卵巢癌发生发展的关联性研究作一简要综述。
Ovarian cancer is one of the common malignant tumors in female genital organs and the biggest killer in female reproductive system tumors. With the further development of molecular genetics and tumor biology research, genetic diagnosis has become an important method to treat malignant tumors. Therefore, it is of great significance to study the molecular genetic mechanism of ovarian cancer and understand its biological effects on the occurrence, development, treatment and prognosis of ovarian cancer. A large number of clinical pathology and molecular genetics experiments show that ERK1 / 2 pathway abnormal activity and low serous ovarian cancer are closely related to the occurrence and development. The article will give a brief overview of the relationship between abnormal sustained activation of ERK1 / 2 pathway (secondary effect of KRAS or BRAF mutation) and the development of low grade serous ovarian cancer.